Main content

    Alzheimer's Disease Clinical Trials

    Sutter Health participates in clinical trials related to Alzheimer's Disease throughout their Northern California facilities. See the listing below for an overview of current trials, including contact information. For some trials, more detailed information can be found via the title link to ClinicalTrials.gov.

    Title: A Randomized Double-Blinded Placebo-Controlled Exploratory Study of Intravenous Immunoglobulin (NewGam 10%) in Amnestic Mild Cognitive Impairment (Protocol IVIG-Kile-032010)Opens in a new window external site
    Description: This study will evaluate the efficacy of intravenous immunoglobulin in patients with  Mild Cognitive Impairment for prevention or delaying progression to Alzheimer Disease Dementia  over 24 months after the infusions . This study will also document  brain volumetrics.
    Investigator: Shawn Kile, MD
    Eligibility: Age from 50 to < 85 years old. Diagnosis of Mild Cognitive Impairment, Amnestic type.
    Status: Active and open to enrollment
    Location: Sutter Medical Center, Sacramento
    Contact: Tammy Donnel, CRC 916-453-5994 Email: Donnelt@sutterhealth.org

    Title: Prediction of Cognitive Decline with MRI and MRSI
    Decscription: Testing of memory functions using brain scans and neuropsycholgical tests .
    Investigator: Susan Woolley, PhD
    Eligibility: Subjects 60 years of age or older who have mild problems with their memory and are comfortable undergoing MRI; healthy volunteers are also needed.
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Dr. Woolley, PhD 415-600-1261
    Email: WoolleS@sutterhealth.org

    Title: A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease
    Decscription: The purpose of this study is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of Alzheimer's Disease (AD). The primary study hypotheses are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score and that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score.
    Investigator: Shawn Kile, MD
    Eligibility: Patients 55-85 with mild to moderate Alzheimer's disease with a realible trial partner that has a close relationship to the patient. Patient must be comfortable undergoing MRI and eye exams. Patient cannot have allergies or hypersensitivity reactions to more than 3 medications.
    Status: Active and open to enrollment.
    Location: Sutter Medical Group | Sutter Institute for Medical Research
    Contact: Tammy Donnel, CRC, 916-453-5994
    Email: Donnelt@sutterhealth.org

    > See All Neurology Clinical Trials by Condition